Orphan designation: N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide Treatment of schwannoma, 06/06/2012 Withdrawn

Orphan designation: Letermovir Treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity, 06/06/2012 Withdrawn

Orphan designation: N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide Treatment of meningioma, 06/06/2012 Withdrawn

Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Date of authorisation: 25/04/2016, Revision: 22, Status: Authorised

Orphan designation: (S)-12-fluoro-4-(2-methylpyridin-3-yl)-7a,8,13,14-tetrahydro-7H-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine Treatment of sickle cell disease, 16/03/2022 Withdrawn

Orphan designation: carbetocin Treatment of Prader-Willi syndrome, 21/03/2012 Withdrawn

Orphan designation: 5-fluoro-4-(7'-fluoro-2'-methylspiro[cyclopentane-1,3'-indol]-5'-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine,crozbaciclib Treatment of glioma, 26/03/2021 Withdrawn

Orphan designation: N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide Treatment of hepatocellular carcinoma, 23/08/2017 Withdrawn

Orphan designation: Eculizumab Treatment of Guillain-Barré syndrome, 11/10/2022 Withdrawn

Orphan designation: amatuximab Treatment of malignant mesothelioma, 16/01/2014 Withdrawn